Access comprehensive financial analyses and make smarter investments - get the Manual of Investments on Amazon!

GH

GH Stock Nears 52-Week High

Shares of Guardant Health rose to $106.97 during today's afternoon trading session. Despite the 6.7% change, the Large-Cap Medical Specialities company still trades 8.05% above its average analyst target price of $99.0. So there may be further downside for the Medical Specialities stock. Guardant Health has target prices ranging from $60.0 to $120.0 per share, and its average rating is buy.

Guardant Health has an average level of shares sold short, at 7.0% of its total share float. The stock's short ratio (also called days to cover) is 3.31. The company's insiders own 4.18% of its outstanding shares, which indicates a strong alignment between management and shareholder interests.

Institutional investors own 97.0% of Guardant Health's shares, which indicates they have a high level of confidence in the company.

Institutions Invested in Guardant Health

Date Reported Holder Percentage Shares Value
2025-09-30 Vanguard Group Inc 9% 11,908,829 $1,273,915,981
2025-09-30 Blackrock Inc. 9% 11,429,315 $1,222,621,219
2025-09-30 BAILLIE GIFFORD & CO 4% 5,127,692 $548,521,503
2025-09-30 Invesco Ltd. 4% 4,929,543 $527,325,030
2025-09-30 Capital International Investors 4% 4,689,241 $501,619,349
2025-09-30 Price (T.Rowe) Associates Inc 3% 4,221,637 $451,598,628
2025-09-30 Deep Track Capital, Lp 3% 4,154,086 $444,372,536
2025-09-30 Eventide Asset Management LLC 3% 3,321,338 $355,291,486
2025-09-30 Wellington Management Group, LLP 3% 3,249,085 $347,562,410
2025-09-30 Geode Capital Management, LLC 2% 2,936,656 $314,141,131
The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.

IN FOCUS